EC Number   |
Substrates |
Organism |
Products |
Reversibility |
|---|
   2.4.1.244 | more |
the enzyme could transfer GalNAc residues, producing N,N'-diacetylgalactosediamine structures at least in N-glycans and probably in both N- and O-glycans |
Homo sapiens |
? |
- |
? |
| 2.4.1.244 | more |
the most efficient acceptor substrate in the N-glycans examined is a non-fucosylated bi-antennary one. The enzyme shows no activity towards chondroitin-related acceptors containing GlcUA as their non-reducing termini |
Homo sapiens |
? |
- |
? |
| 2.4.1.244 | more |
flies mutant for beta4GalNAcTA are viable and fertile but display behavioral phenotypes suggestive of essential roles for GalNAc-beta1,4-GlcNAc containing glycoconjugates in neuronal and/or muscular function |
Drosophila melanogaster |
? |
- |
? |
| 2.4.1.244 | more |
flies mutant for beta4GalNAcTB are viable and display no evident morphological or behavioral phenotypes |
Drosophila melanogaster |
? |
- |
? |
| 2.4.1.244 | more |
no activity with GalNac |
Drosophila melanogaster |
? |
- |
? |
| 2.4.1.244 | more |
the enzyme mediates the protein-specific addition of beta1,4-linked GalNAc to core 2 O-linked structures both in vivo and in vitro |
Homo sapiens |
? |
- |
? |
| 2.4.1.244 | more |
enzyme B4GALNT3 primarily modifies N-glycans of epithelial growth factor receptor, EGFR, in LacdiNAc by Wisteria floribunda agglutinin pull down assays |
Homo sapiens |
? |
- |
? |
| 2.4.1.244 | UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
26.2% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
Homo sapiens |
UDP + Gal-beta-(1,4)-GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
? |
| 2.4.1.244 | UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
45% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
Homo sapiens |
UDP + Gal-beta-(1,4)-GalNAc-beta(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
- |
? |
| 2.4.1.244 | UDP-GalNAc + Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside |
26.7% of the activity with GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-GlcNAc-2-pyridylaminoside |
Homo sapiens |
UDP + GalNAc-beta(1,4)-Gal-beta-(1,4)-GlcNAc-beta-(1,2)-Man-alpha-(1,6)-[GlcNAc-beta-(1,2)-Man-alpha-(1,3)]Man-beta-(1,4)-GlcNAc-beta-(1,4)-[Fuc-alpha-(1,6)]-GlcNAc-2-pyridylaminoside |
- |
? |
